EverX Participates in Biotech Showcase Following CES Appearance

EverX booth set up at CES 2023. (Photo by EverX)

[Asia Economy Reporter Chunhee Lee] Digital therapy solution startup Everex announced on the 11th that it has begun actively advancing its global business by consecutively participating in CES 2023, the world's largest electronics and IT exhibition held in Las Vegas, USA from the 5th to the 8th (local time), and the 'Biotech Showcase 2023' held in San Francisco, USA from the 9th to the 11th.

During CES 2023, Everex showcased 'MORA,' a musculoskeletal disease rehabilitation and exercise therapy solution based on pose-estimation artificial intelligence (AI) technology, at a dedicated booth in the digital health section.

MORA is a digital therapeutic solution for rehabilitation and exercise therapy prescriptions based on AI technology specialized for musculoskeletal diseases and medical evidence. At CES, the pose-estimation AI technology, which accurately recognizes joint points through the camera of a portable device and displays them in real time, attracted significant attention from visitors.

Various business collaboration discussions were also conducted. Everex engaged in talks with domestic large corporations and startups interested in the digital therapeutic device (DTx) field and conducting research and development (R&D), as well as buyers from several overseas countries including the United States, India, Japan, and Taiwan.

Everex also participated in the Biotech Showcase 2023, held alongside the JP Morgan Healthcare Conference from the 9th to the 11th, and introduced the company on the 9th.

Yoon Chan, CEO of Everex, said, “This year, we aim to supply the MORA service to medical institutions in the United States,” adding, “The U.S. already has active use of DTx in the rehabilitation exercise field, and reimbursement policies are set, so positive results are expected.” He continued, “Through this global event, we were able to reaffirm the value and business competitiveness of MORA and concretize commercialization through networking with companies and investors who have already entered the U.S. medical market.”

Everex plans to prepare for DTx approval through ongoing clinical trials for each musculoskeletal disease while concretizing services and business models suitable for overseas markets such as the United States. Through this, the company envisions starting to generate sales in the U.S. market within the second half of this year.